Ligand Pharmaceuticals (LGND) Intangibles (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Intangibles data on file, last reported at $217.3 million in Q1 2026.

• For the quarter ending Q1 2026, Intangibles fell 15.89% year-over-year to $217.3 million; the trailing twelve-month figure through Mar 2026 stood at $217.3 million (down 15.89% YoY), and the FY2025 full-year result was $225.4 million, down 15.45% from the prior year.
• Intangibles declined to $217.3 million in Q1 2026, from $225.4 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $539.7 million in Q1 2022 to a low of $217.3 million in Q1 2026.
• A 5-year average of $323.7 million and a median of $291.4 million in 2024 frame the typical range for Intangibles.
• Across the five-year window, Intangibles declined 7.55% in 2022 and slumped 39.1% in 2023, its largest moves.
• Tracing LGND's Intangibles over 5 years: stood at $342.5 million in 2022, then dropped by 12.51% to $299.6 million in 2023, then retreated by 11.0% to $266.6 million in 2024, then declined by 15.45% to $225.4 million in 2025, then fell by 3.59% to $217.3 million in 2026.
• Business Quant data shows LGND's Intangibles at $217.3 million in Q1 2026, $225.4 million in Q4 2025, and $233.5 million in Q3 2025.